Skin-on-a-Chip: Transepithelial Electrical Resistance and Extracellular Acidification Measurements through an Automated Air-Liquid Interface

Alexander, F.; Eggert, Sebastian; Wiest, J.

doi:10.3390/genes9020114

Cited by 65 publications

(45 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OOAC technology has developed rapidly in recent years and has enhanced our knowledge of all the major organs. Others not discussed in this review include blood vessels [99,114,115], the skin [116,117], the BBB [118,119], skeletal muscle [120,121], and the CNS [122,123].…”

Section: Multi-organs-on-a-chipmentioning

confidence: 99%

Organ-on-a-chip: recent breakthroughs and future prospects

et al. 2020

View full text Add to dashboard Cite

BackgroundMicrofluidics is a science and technology that precisely manipulates and processes microscale fluids. It is commonly used to precisely control microfluidic (10 −9 to 10 −18 L) fluids using channels that range in size from tens to hundreds of microns and is known as a "lab-on-a-chip" [1][2][3][4]. The microchannel is small, but has a large surface area and high mass transfer, favoring its use in microfluidic technology applications including low regent usage, controllable volumes, fast mixing speeds, rapid responses, and precision control of physical and chemical properties [1,5,6]. Microfluidics integrate sample preparation, reactions, separation, detection, and basic operating units such as cell culture, sorting and cell lysis [7]. For these reasons, interest in OOAC has intensified [8]. OOAC combines a range of chemical, biological and material science disciplines [9] and was selected as one of the "Top Ten Emerging Technologies" in the World Economic Forum [10].OOAC is a biomimetic system that can mimic the environment of a physiological organ, with the ability to regulate key parameters including AbstractThe organ-on-a-chip (OOAC) is in the list of top 10 emerging technologies and refers to a physiological organ biomimetic system built on a microfluidic chip. Through a combination of cell biology, engineering, and biomaterial technology, the microenvironment of the chip simulates that of the organ in terms of tissue interfaces and mechanical stimulation. This reflects the structural and functional characteristics of human tissue and can predict response to an array of stimuli including drug responses and environmental effects. OOAC has broad applications in precision medicine and biological defense strategies. Here, we introduce the concepts of OOAC and review its application to the construction of physiological models, drug development, and toxicology from the perspective of different organs. We further discuss existing challenges and provide future perspectives for its application.

show abstract

Section: Multi-organs-on-a-chipmentioning

confidence: 99%

Organ-on-a-chip: recent breakthroughs and future prospects

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The incorporation of biosensors with biochips provides in situ and real-time monitoring of skin tissue responses to the test item. A sophisticated skin-on-a-chip platform integrated with a sensor was developed by Alexander et al [132] for monitoring the transepithelial electrical resistance of recreated human epidermis. Metabolic parameters and change of skin tissue over time have been monitored in this platform.…”

Section: Skinmentioning

confidence: 99%

Evolution of Biochip Technology: A Review from Lab-on-a-Chip to Organ-on-a-Chip

et al. 2020

View full text Add to dashboard Cite

Following the advancements in microfluidics and lab-on-a-chip (LOC) technologies, a novel biomedical application for microfluidic based devices has emerged in recent years and microengineered cell culture platforms have been created. These micro-devices, known as organ-on-a-chip (OOC) platforms mimic the in vivo like microenvironment of living organs and offer more physiologically relevant in vitro models of human organs. Consequently, the concept of OOC has gained great attention from researchers in the field worldwide to offer powerful tools for biomedical researches including disease modeling, drug development, etc. This review highlights the background of biochip development. Herein, we focus on applications of LOC devices as a versatile tool for POC applications. We also review current progress in OOC platforms towards body-on-a-chip, and we provide concluding remarks and future perspectives for OOC platforms for POC applications.

show abstract

“…Monocytes (U937) have been co-cultured with HaCat keratinocyte-based epidermis in a bi-channel microfluidic setting for up to 17 days (Ramadan and Ting, 2016). Many skin-on-chip platforms contribute to drug development as biosensors can be implemented to provide non-invasive realtime tissue response readouts (e.g., membrane permeability and skin metabolism), which help in determining drug efficacy and toxicity (Wang Y. I. et al, 2017;Zhang et al, 2017;Alexander et al, 2018).…”

Section: Skin Organoidsmentioning

confidence: 99%

Utilizing Organoid and Air-Liquid Interface Models as a Screening Method in the Development of New Host Defense Peptides

Choi

Lee

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Host defense peptides (HDPs), also known as antimicrobial peptides, are naturally occurring polypeptides (∼12-50 residues) composed of cationic and hydrophobic amino acids that adopt an amphipathic conformation upon folding usually after contact with membranes. HDPs have a variety of biological activities including immunomodulatory, anti-inflammatory, anti-bacterial, and anti-biofilm functions. Although HDPs have the potential to address the global threat of antibiotic resistance and to treat immune and inflammatory disorders, they have yet to achieve this promise. Indeed, there are several challenges associated with bringing peptide-based drug candidates from the lab bench to clinical practice, including identifying appropriate indications, stability, toxicity, and cost. These challenges can be addressed in part by the development of innate defense regulator (IDR) peptides and peptidomimetics, which are synthetic derivatives of HDPs with similar or better efficacy, increased stability, and reduced toxicity and cost of the original HDP. However, one of the largest gaps between basic research and clinical application is the validity and translatability of conventional model systems, such as cell lines and animal models, for screening HDPs and their derivatives as potential drug therapies. Indeed, such translation has often relied on animal models, which have only limited validity. Here we discuss the recent development of human organoids for disease modeling and drug screening, assisted by the use of omics analyses. Organoids, developed from primary cells, cell lines, or human pluripotent stem cells, are three-dimensional, self-organizing structures that closely resemble their corresponding in vivo organs with regards to immune responses, tissue organization, and physiological properties; thus, organoids represent a reliable method for studying efficacy, formulation, toxicity and to some extent drug stability and pharmacodynamics. The use of patient-derived organoids enables the study of patient-specific efficacy, toxicogenomics and drug response predictions. We outline how organoids and omics data analysis can be leveraged to aid in the clinical translation of IDR peptides.

show abstract

Skin-on-a-Chip: Transepithelial Electrical Resistance and Extracellular Acidification Measurements through an Automated Air-Liquid Interface

Cited by 65 publications

References 26 publications

Organ-on-a-chip: recent breakthroughs and future prospects

Organ-on-a-chip: recent breakthroughs and future prospects

Evolution of Biochip Technology: A Review from Lab-on-a-Chip to Organ-on-a-Chip

Utilizing Organoid and Air-Liquid Interface Models as a Screening Method in the Development of New Host Defense Peptides

Contact Info

Product

Resources

About